February 28, 2014 -- ClinTec International celebrates Rare Disease Day on the 28th February 2014 as an act of full solidarity with all patients suffering from rare disease conditions. It is hoped that such an expression of support will make a meaningful difference to all those with Rare Disease across the globe. ClinTec, together with other healthcare sector companies, are keen to let patients with Rare Disease know that they are all in this together as the challenge to advance treatments continues to expand.
Over the past few years, a dynamic relationship has evolved between ClinTec International and research into patients with Rare Diseases. ClinTec has several programs in Rare Disease running globally. In 2007, the company assisted in phase III trials in Thalassemia in Egypt, which successfully closed out. ClinTec has experience in several natural history and pharmaceutical trials including Niemann Pick’s Disease, Gaucher’s Disease, Wolman’s Disease and other Lysosomal storage disorder studies. ClinTec employees have been working extensively on long term study programs.
The company is passionate about the studies that they handle. ClinTec understands the overwhelming experience of patients who do not have much knowledge or have no available treatment for the condition and very often struggle beyond the condition itself with misdiagnoses, failed treatments and great expenses. However, advancements in the field of Rare Disease have gained momentum in the past few years.
Research into rare disease offers opportunities to uncover findings that can lead to significant breakthroughs. With experience in having conducted studies in various regions, ClinTec is able to provide strategic solutions from the starting point of gaining new insight in various areas. The knowledge gained from Natural History studies serves as the foundation to plan and design studies in various regions.
As a Clinical Research Organisation, ClinTec International plays a pivotal role in all phases of the drug development process. ClinTec has partnered with pharmaceutical and biopharmaceutical companies to bring life-saving drugs to patients who have minimal or no access to these drugs, for example in the MENA region. ClinTec has vast experience in dealing with the complexities of such trials including in paediatric populations and the obstacles they present. The dedicated teams at ClinTec are acutely aware of the importance of patient referral networks for achieving recruitment targets and the use of study and disease awareness campaigns and materials to identify referring investigators and ensure the targeted patient populations have all background information necessary.
It is ClinTec’s passion for supporting research in Rare Disease that has helped its teams to learn and grow operations in different regions of the world. ClinTec is attending the World Orphan Drug Congress in Washington D.C, US on the 23rd to 25th April 2014.
ClinTec’s vast experience is the motivation for greater collaboration towards innovative therapies and to enable access of life saving medications to patients with Rare Disease.
ClinTec encourages everyone to join in to show their support to inspire others in this critical field.
About ClinTec International
ClinTec is a global contract clinical research organisation, established in 1997 by Dr Rabinder Buttar, the company’s President and CEO. ClinTec has a presence in over 50 countries, covering Western Europe, Central & Eastern Europe, the Middle East and North Africa, Central and South Africa, Latin America, India and the US.
In addition to ClinTec’s vast expertise in oncology, rare disease and diabetes, the organisation has also conducted over 250 clinical trials in other therapeutic areas including anti-infectives, cardiology, dermatology, gastroenterology, neurology, respiratory medicine and rheumatology. ClinTec International excels in conducting clinical studies in diverse geographical locations, supported by a team of world-class project managers and clinical research associates. ClinTec’s fast, flexible and focused approach to clinical research ensures an added advantage to the drug development process.
For media enquiries, please contact Tristan Jervis on +44 (0) 207 203 6740 or e-mail: t.jervis@defacto.com.
If you would like further information on ClinTec International, please contact:
Bobby Bal, Vice President – ClinTec International Group
Glasgow, Scotland, UK.
Phone: +44 (0)141 226 1120
Fax: +44 (0)141 248 8993
Email: bbal@clintec.com
Website: www.clintec.com
Help employers find you! Check out all the jobs and post your resume.
